sb 239063 has been researched along with Amyotrophic Lateral Sclerosis in 1 studies
SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.
Amyotrophic Lateral Sclerosis: A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gibbs, KL | 1 |
| Kalmar, B | 1 |
| Rhymes, ER | 1 |
| Fellows, AD | 1 |
| Ahmed, M | 1 |
| Whiting, P | 1 |
| Davies, CH | 1 |
| Greensmith, L | 1 |
| Schiavo, G | 1 |
1 other study available for sb 239063 and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS.
Topics: Acetylcarnitine; Amyotrophic Lateral Sclerosis; Animals; Axonal Transport; Disease Models, Animal; E | 2018 |